AngioDynamics Stock Up on Q2 Earnings Beat, Gross Margin Declines
ANGO registers overall strong top-line results on a pro-forma basis in second-quarter fiscal 2025, driven by strength in the Med Tech business.
Prediction & Performance
ABT
PryogiTM predictions explained
Predicted Price is the pryogiTM prediction of where the price is going in next 3-4 quarters. There may be a revision of the predicted price every 3 months from the date of publication of the first predicted price of the stock. Price on Report Date is the price of the stock on the day prediction was published by pryogiTM. Current price shows the current price of the stock.
Margin of error shows range the price will end up in dollars either above or below the predicted price. Margin of error percentage shows the price will end up in percentage either above or below the predicted price.
Expected Returns from report date shows the returns (positive or negative) from published prediction date if you bought the stock on report date. Expected Returns from today shows the returns from today if you buy the stock today. A positive expected returns indicates a profit you will make, a negative expected return indicates a loss you will make if you buy the stock. There are different strategies to apply in the stock market for profit and loss, pryogiTM will publish such strategies in the future to help you.
PryogiTM meter explained
PryogiTM meter shows you predicted price, price on the date this prediction was published(report date) and price of the stock today on a price scale. This indicates if the stock price is moving towards or away from the predicted price
PryogiTM performance chart explained
PryogiTM performance chart shows actual movement of stock price from prediction published date(report date) and if the price is moving towards or away from predicted price
Abbott Laboratories(ABT) news
Tempus AI Stock Falls Despite Collaboration Announcement With Genialis
TEM announces a collaboration with Genialis to develop new RNA-based algorithms across cancer types.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK's growth is fueled by Rayaldee's success and accelerated clinical trials. However, stiff competition and overdependence on its lead product are concerns.
Abbott Stock Trades at a Discounted P/B Value: To Buy or Not to Buy?
ABT gains a key position in point-of-care testing, focusing on Infectious Disease, Cardiometabolic & Informatics, Toxicology and Consumer Diagnostics.
BDSX Stock Rises After Publication of Study Data for Nodify CDT Test
Biodesix announces positive study data for its Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal.
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst - Abbott Laboratories ( NYSE:ABT ) , Anteris Technologies ( NASDAQ:AVR )
Barclays analyst Matt Miksic initiated coverage on Anteris Technologies Global Corp. AVR with a Positive rating and a forecast of $22. The analyst notes that Anteris Technologies' DurAVR valve system is expected to become the second balloon-expandable transcatheter valve replacement ( BEV TAVR ) ...
Here's Why You Should Retain BDX Stock in Your Portfolio for Now
BD's robust product portfolio and a few strategic deals raise optimism about the stock. However, stiff competition and macroeconomic volatility are concerns.
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer - Bright Minds Biosciences ( NASDAQ:DRUG )
-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy --
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 ( GLOBE NEWSWIRE ) -- Bright Minds Biosciences, Inc. ( "Bright Minds," "BMB" or the "Company" ) ( NASDAQ: DRUG ) , a pioneering company focused on ...
Polyneuropathy Treatment Market is Projected to Grow at a 4.9% CAGR, Reaching US$ 3.31 Billion by 2034 | Fact.MR Report
Rockville, MD , Jan. 07, 2025 ( GLOBE NEWSWIRE ) -- According to Fact.MR, a market research and competitive intelligence provider, the global Polyneuropathy Treatment Market is set to reach US$ 2.05 billion in 2024 and further expand at a CAGR of 4.9% from 2024 to 2034.
TMCI Stock May Gain From the Limited Release of the Percuplasty System
Treace Medical announces the limited market release of the Percuplasty Percutaneous 3D Bunion Correction System, targeting the in-demand bunion surgery market.
Omnicell Gains 26.2% in a Year: What's Driving the Stock?
OMCL's shares rise on the back of its XT Amplify program gaining market traction with its initial offerings. However, the unfavorable macroeconomic scenario is concerning.
EssilorLuxottica to Acquire Pulse Audition: Will the Stock Rise?
ESLOY is set to acquire Pulse Audition, an AI-driven tech startup, to strengthen its position in the hearing solution space.
2 No-Brainer Dividend Stocks to Buy With $250 in 2025
When it comes to dividend investing, there are two basic paths you can take. You could seek out businesses that are raising their payouts at a rapid pace, but these stocks tend to offer low yields. The other basic option available to dividend investors is to buy stocks with really high yields.
3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
If you're worried about having enough passive income to maintain your lifestyle during retirement, you're not alone. Having to spend more just to maintain their current standard of living is a constant concern for most families.There isn't much that you can do to stop the march of inflation, but ...
Cencora Stock May Gain Following the Strategic Acquisition of RCA
COR completes the acquisition of Retina Consultants of America, marking a significant step in expanding its specialty healthcare and MSO solutions.
Reasons to Add Cardinal Health Stock to Your Portfolio Now
CAH continues to grow on the back of its robust product portfolio and a strong quarterly result.
ResMed Gains 37.8% in a Year: What's Driving the Stock?
RMD's shares gain on the back of robust mask and device sales growth. However, the unfavorable macroeconomic scenario is concerning.
Here's Why You Should Add MMSI Stock to Your Portfolio Now
Merit Medical's strong product portfolio raises optimism about the stock.
3 Dividend Growth Beasts That Have Raised Their Payouts for a Combined 165 Years
Want some solid dividend growth stocks with incredible track records of increasing their payouts? Here's a list of stocks that have been raising their dividend payments consistently for more than 50 consecutive years.
Inogen Stock Rises as FDA Clears SIMEOX 200 Airway Clearance Device
INGN announces FDA clearance for the SIMEOX 200 Airway Clearance Device.
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
RVTY's strong product portfolio raises optimism about the stock.
How Is The Market Feeling About Abbott Laboratories? - Abbott Laboratories ( NYSE:ABT )
Abbott Laboratories's ABT short percent of float has fallen 11.39% since its last report. The company recently reported that it has 12.10 million shares sold short, which is 0.7% of all regular shares that are available for trading.
Here's Why You Should Retain Integer Holdings Stock in Your Portfolio
ITGR's research and product development activities raise optimism about the stock. Rising demand for its products bodes well for the company.
5 MedTech Stocks That Are Poised to Beat the Market in 2025
Here, we discuss five stocks that are likely to generate better than the market, driven by strong demand for existing products and the addition of innovative new devices.
Abbott Laboratories(ABT) news
2 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
A few different elements can make a stock a no-brainer buy. The company could be the leader in its market, or well diversified across various markets. In any case, it should have a solid track record of earnings growth and promising long-term prospects.
HealthEquity Gains 46.8% in a Year: What's Driving the Stock?
HQY's sustained strength in HSAs raises optimism about the stock.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
ECL continues to gain from its strong segmental performance and improved operating margin.
Growing Biosimilars Business, New Partnerships Support ABT Stock
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
OSUR Stock Rises Following the Acquisition of Sherlock Biosciences
OraSure announces acquisition of Sherlock Biosciences to strengthen its molecular diagnostics portfolio.
Is Abbott Stock Worth Buying at a Discounted P/S Valuation?
Abbott's strong market position, promising growth prospects and consistent share gains make it a compelling pick for investors.
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA
GKOS announces New Drug Application submission for its Epioxa to the FDA.
Integer Holdings Gains 34.4% in One Year: What's Driving the Stock?
ITGR shares gain on the back of growth in the Medical segment. However, dependence on third-party suppliers is concerning.
Ensign Expands Footprint With Buyout of Eight Healthcare Facilities
ENSG agrees to buy eight healthcare facilities from Providence Home and Community Care, expanding its footprint.
Merit Medical Stock Rises Following FDA Nod for WRAPSODY Device
MMSI announces FDA approval for the WRAPSODY Cell-Impermeable Endoprosthesis.
2 Excellent Dividend Stocks to Buy on the Dip
AbbVie ( NYSE: ABBV ) and Amgen ( NASDAQ: AMGN ) have a lot in common. They are both leading drugmakers and have strong dividend track records. Both also recently saw their shares fall significantly in one day, following unimpressive clinical data for otherwise promising candidates.Despite their ...
My Top 10 Stocks to Buy for 2025
It's that time of year again. I'm not referring to buying gifts and preparing holiday meals -- although that may be part of your agenda too. It's time to look back on your portfolio's performance and plan for the year ahead.It's been a solid year for many, with all three indexes heading for ...
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.
The Zacks Analyst Blog Highlights Veracyte, Omnicell, Masimo and Abbott Laboratories
Veracyte, Omnicell, Masimo and Abbott Laboratories are included in this Analyst Blog.
Adobe Stock Slips 20% in a Week: Should You Brace for a Tough 2025?
ADBE shares are benefiting from strong demand for its creative products and expanding clientele amid increasing competition and stretched valuation.
4 Healthcare Technology Innovators to Invest in Before the New Year
Here, we have presented four healthcare technology stocks for stable portfolio gains in 2025: VCYT, OMCL, MASI and ABT.
Reasons to Retain ABT Stock in Your Portfolio Now
Investors feel optimistic about Abbott's robust strength in the EPD and Nutrition businesses. Yet, unfavorable forex impacts are concerning.
2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond
What will be the hottest investing trend on Wall Street next year? Maybe artificial intelligence will keep up its momentum, or perhaps interest in weight loss-focused pharmaceutical companies will increase. Whatever the answer is, it probably won't be dividend investing.
ABT Stock Up on First Successful LBBAP Procedures With AVEIR Pacemaker
Abbott completes the world's first leadless pacing procedures in the left bundle branch of the heart.
Reasons to Retain GE HealthCare Stock in Your Portfolio Now
GEHC's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
Reasons to Add McKesson Stock to Your Portfolio Right Now
MCK's strategic collaborations and strength in Biologics raise optimism about the stock.
The Smartest Dividend Stocks to Buy With $500 Right Now
As an investor, your goal is to select quality stocks that will advance over a period of years -- but this doesn't mean you have to wait a long time for all of the rewards. If you add a few dividend stocks to your portfolio, you'll start collecting returns on a regular basis -- without lifting a ...
Protein Hydrolysate Ingredient Market Projects to reach US$ 6.15 billion Valuation by 2034
Rockville Pike, Dec. 18, 2024 ( GLOBE NEWSWIRE ) -- The global protein hydrolysate ingredient market is projected to reach US$ 6.15 billion by the end of 2034, up from US$ 3.53 billion in 2024, according to a new industry analysis compiled by Fact.MR.
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors - Assertio Holdings ( NASDAQ:ASRT )
LAKE FOREST, Ill., Dec. 17, 2024 ( GLOBE NEWSWIRE ) -- Assertio Holdings, Inc. ( "Assertio" or the "Company" ) ASRT, a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an ...